MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202421007180 A) filed by Anand Radheshyam Tiwari, Vasai, Maharashtra, on Feb, 2, 2024, for 'a comprehensive stability-indicating method for escitalopram analysis by rp-hplc.'
Inventor(s) include Anand Radheshyam Tiwari; Dr. Sushama R. Amabadekar; and Vijay Arjun Bagul.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "Disclosed herein is amethod (100) for comprehensive Escitalopram impurity 5 analysis. The method (100) involves stages such as sample preparation (102) with filtration and injection into RP-HPLC, mobile phase formulation (104) adhering to green analytical chemistry principles, chromatographic conditions setup (106) configuring RP-HPLC with a C18 column for optimal separation, and detector configuration (108) setting up a diode array detector at 240nm. Sample injection (110) 10 includes injecting 5l into RP-HPLC, and elution and separation (112) monitors compounds through the column. Validation procedures (114) assess precision, accuracy, and detection limits per ich guidelines. Robustness testing (116) introduces variations, stability testing (118) evaluates under stress conditions, and degradation studies (120) ensure specificity. Data analysis (122) quantifies compounds, method 15 optimization (124) refines parameters, and documentation (126) records procedures and results."
Disclaimer: Curated by HT Syndication.
